Discounted Cash Flow (DCF) Analysis Levered

Skye Bioscience, Inc. (SKYE)

$0.028

+0.01 (+24.44%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 0.028
Beta 0.222
Diluted Shares Outstanding 406.60
Cost of Debt
Tax Rate -0.02
After-tax Cost of Debt 35.93%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.542
Total Debt 2.14
Total Equity 11.38
Total Capital 13.52
Debt Weighting 15.80
Equity Weighting 84.20
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.50
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -6.85
Equity Value -
Shares Outstanding 406.60
Equity Value Per Share -